2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Fintepla - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:		Prescriber Name:	
Member Number:		Fax: Phone:	
Date of Birth:		Office Contact:	
Line of Business:	□ Medicare	NPI: State Lic ID:	
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Primary Phone:		Specialty/facility name (if applicable):	
	<u>DITED REVIEW</u> : By checking this box and signing below, I nrollee or the enrollee's ability to regain maximum funct	certify that applying the 72 hour standard review timeframe may seriously jeopardize ion.	
Drug Name:			
Strength:			
Directions / SIG:			
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Does the patient have hypersensitivity to Fintepla or any of the components of Fintepla?			
☐ Yes		□ No	
Q2. Does the patient have a documented diagnosis of Dravet syndrome (DS)?			
☐ Yes		□ No	
Q3. Is there documentation of an inadequate response or intolerance to at least two of agents to treat Dravet syndrome: such as clobazam, valproic acid derivatives, topiramate, levetiracetam, cannabidiol (pharmaceutical), or stiripentol. (Include dates, duration, and outcome of agent tried)?			
☐ Yes		□ No	
Q4. Does the patient have a documented diagnosis of Lennox-Gastaut syndrome (LGS)?			
□Yes		□No	
Q5. Is there documentation showing an inadequate response or intolerance to at least two agents to treat Lennox-Gastaut syndrome (LGS): such as lamotrigine, rufinamide, topiramate,			

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Fintepla - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:	
cannabidiol (pharmaceutical), clobazam, felbamate. (Include dates, duration, and outcome of tried drugs)?		
☐ Yes	□ No	
Q6. Is the patient 2 years of age or older?		
☐ Yes	□ No	
Q7. Is Fintepla being prescribed by or in consultation with a neurologist or epileptologist?		
☐ Yes	□ No	
Q8. Will Fintepla will be used with or within 14 days of administration of monoamine oxidase inhibitors?		
☐ Yes	□ No	
Q9. Will patient have required echocardiogram monitoring?		
☐ Yes	□ No	
Q10. Requested Duration:		
☐ 12 Months	☐ Other:	
Q11. Additional Information:		
Prescriber Signature	Date	
	2024 Medicare Prior Authorization Request	